Evidence map›Paper›PMID 36426199›Full record

ArticleOpen access rheumatology : research and reviews2022

Better Clinical Results in Rheumatoid Arthritis Patients Treated Under a Multidisciplinary Care Model When Compared with a National Rheumatoid Arthritis Registry.

Pedro Santos-Moreno, Gabriel-Santiago Rodríguez-Vargas, Susan Martínez, Linda Ibatá, Laura Villarreal-Peralta, Anggie Aza-Cañon, Manuel Rivero, Pedro Rodriguez, Adriana Rojas-Villarraga

Open access · goldAbstract read
In one paragraph

Article in Open access rheumatology : research and reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Pedro Santos-MorenoRheumatology Department, Biomab IPS, Bogotá, Colombia.ORCID 0000-0001-7802-0317
Gabriel-Santiago Rodríguez-VargasRheumatology Department, Biomab IPS, Bogotá, Colombia.ORCID 0000-0003-1613-7100
Susan MartínezEpidemiology Department, Epithink Health Consulting, Bogotá, Colombia.ORCID 0000-0002-6847-3408
Linda IbatáEpidemiology Department, Epithink Health Consulting, Bogotá, Colombia.ORCID 0000-0002-7191-7313
Laura Villarreal-PeraltaRheumatology Department, Biomab IPS, Bogotá, Colombia.ORCID 0000-0002-8366-9169
Anggie Aza-CañonRheumatology Department, Biomab IPS, Bogotá, Colombia.
Manuel RiveroRheumatology Department, Biomab IPS, Bogotá, Colombia.
Pedro RodriguezRheumatology Department, Biomab IPS, Bogotá, Colombia.ORCID 0000-0002-3319-2577
Adriana Rojas-VillarragaResearch Institute, Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia.ORCID 0000-0003-3145-2440
Fundación Universitaria de Ciencias de la Salud · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To describe clinical characteristics and effectiveness of health care in patients with rheumatoid arthritis (RA) as part of a multidisciplinary care model (MCM) in a specialized rheumatology center, compared with the results of a national registry of RA (NARRA) as evidence of real-world management. Patients and Methods: We conducted a real-world study (July 1, 2018 to June 30, 2019) based on an analysis of electronic health records of a cohort of RA patients managed with the "Treat-to-Target" strategy in a specialized rheumatology center in Colombia with an MCM, compared with the NARRA that includes different models of usual care. Results: We have analyzed 7053 subjects with RA treated at a specialized rheumatology center and 81,492 patients from the NARRA. Cohorts were similar in their baseline characteristics, with women in predominance and diagnosis age close to 50 years. At the time of diagnosis, a higher proportion of clinical diagnostic test use and rheumatology consultation access was observed in the specialized rheumatology center than in the national registry (4-6 per year versus three or less). In addition, higher proportions of patients in remission and low disease activity were reported for the specialized rheumatology center, with a >40% amount of data lost in the national registry. Pharmacological management was similar regarding the analgesic use. In the specialized center, Certolizumab was more frequently used than in the NARRA registry; also, there were significant differences in methotrexate, leflunomide, and sulfasalazine use, being higher in the specialized rheumatology center. Conclusion: The MCM of a specialized center in RA can guarantee comprehensive care, with better access to all the services required to manage the disease. It ensures specialist management and evidence-based care that facilitates the achievement of therapeutic objectives. In addition, better patient records and follow-ups are available to evaluate health outcomes.

Indexed as

multidisciplinary healthcarereal-world datarheumatoid arthritistherapeutics

Identifiers

PMID36426199
PMCPMC9680987
OpenAlexW4309614972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.